Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2015 1
2016 1
2018 1
2019 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors.
Leary SES, Onar-Thomas A, Fangusaro J, Gottardo NG, Cohen K, Smith A, Huang A, Haas-Kogan D, Fouladi M; COG Central Nervous System Committee. Leary SES, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30600. doi: 10.1002/pbc.30600. Epub 2023 Aug 3. Pediatr Blood Cancer. 2023. PMID: 37534382
There remain significant challenges to overcome: children with unresectable low-grade glioma may require multiple prolonged courses of therapy affecting quality of life; children with high-grade glioma have a dismal long-term prognosis; children with medulloblastoma may su …
There remain significant challenges to overcome: children with unresectable low-grade glioma may require multiple prolonged courses of thera …
A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
Johnston RL, Mottok A, Chan FC, Jiang A, Diepstra A, Visser L, Telenius A, Gascoyne RD, Friedman DL, Schwartz CL, Kelly KM, Scott DW, Horton TM, Steidl C. Johnston RL, et al. Blood. 2022 Feb 10;139(6):889-893. doi: 10.1182/blood.2021011941. Blood. 2022. PMID: 34662378 Free PMC article. Clinical Trial.
Although cHL is highly curable, treatment with chemotherapy and radiation often come at the cost of long-term toxicity and morbidity. Effective risk-stratification tools are needed to tailor therapy. ...
Although cHL is highly curable, treatment with chemotherapy and radiation often come at the cost of long-term toxicity and morbidity. …
Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Dome JS, Mullen EA, Dix DB, Gratias EJ, Ehrlich PF, Daw NC, Geller JI, Chintagumpala M, Khanna G, Kalapurakal JA, Renfro LA, Perlman EJ, Grundy PE, Fernandez CV. Dome JS, et al. J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070. J Natl Compr Canc Netw. 2021. PMID: 34416705 Free PMC article. Review.
Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lung metastasis with complete lung nodule response after 6 weeks of chemotherapy. ...
Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lun …
Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.
Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA. Wendorff AA, et al. Cancer Discov. 2019 Mar;9(3):436-451. doi: 10.1158/2159-8290.CD-18-1005. Epub 2018 Dec 19. Cancer Discov. 2019. PMID: 30567843 Free PMC article.
Mechanistically, genetic inactivation of Phf6 in the hematopoietic system enhances hematopoietic stem cell (HSC) long-term self-renewal and hematopoietic recovery after chemotherapy by rendering Phf6 knockout HSCs more quiescent and less prone to stress-induced activation. …
Mechanistically, genetic inactivation of Phf6 in the hematopoietic system enhances hematopoietic stem cell (HSC) long-term self-renew …
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.
Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon PS. Matloub Y, et al. Pediatr Blood Cancer. 2016 Feb;63(2):255-61. doi: 10.1002/pbc.25793. Epub 2015 Oct 20. Pediatr Blood Cancer. 2016. PMID: 26485054 Free PMC article.
Overall 7-year survivals were 86.1 4.6%, 88.3 4.4%, 89.1 3.6%, respectively (P = 0.84). CONCLUSIONS: Comparable high rates of EFS and long-term survival were achieved with all three regimens, with the CCG regimens utilizing a less intensive chemotherapy backbone without pr …
Overall 7-year survivals were 86.1 4.6%, 88.3 4.4%, 89.1 3.6%, respectively (P = 0.84). CONCLUSIONS: Comparable high rates of EFS and long- …
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.
Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N. Ebb D, et al. J Clin Oncol. 2012 Jul 10;30(20):2545-51. doi: 10.1200/JCO.2011.37.4546. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665540 Free PMC article. Clinical Trial.
For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 50%, respectively. There was no clinically significant short-term cardiotoxicity in patients treated with trastuzumab and doxorubicin. …
For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 5 …
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT. Gutierrez A, et al. J Clin Oncol. 2010 Aug 20;28(24):3816-23. doi: 10.1200/JCO.2010.28.3390. Epub 2010 Jul 19. J Clin Oncol. 2010. PMID: 20644084 Free PMC article.
These samples represented nine patients who did not achieve an initial complete remission, 13 who relapsed, and 25 who became long-term, event-free survivors. The findings were confirmed in an independent cohort of patients by quantitative DNA polymerase chain reaction (DN …
These samples represented nine patients who did not achieve an initial complete remission, 13 who relapsed, and 25 who became long-term …